ERBB2 and breast cancer: CLEC-2 levels in the luminal B HER2-positive and triple-negative subtypes were significantly lower compared to non-breast cancer controls (222.8 ± 24.9 and 222.2 ± 33.4 vs. 250.3 ± 23.0, respectively; p <0.0001).